This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

LEON GOLDMAN, MD; DONALD J. BLANEY, MD, PhD; WILLIAM COHEN, MD

Arch Dermatol. 1963;88(5):529-530.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The antimetabolite, 5-fluorouracil (5-FU), produces in the skin redness, erosive lesions, and hyperpigmentation after intravenous use and from topical application.^1-4 There has been no note of nail changes except for brief mention of rare hyperpigmentation and transverse sulci after intravenous use. In the course of our studies of the past year with topical 5-FU for the treatment of warts (308 patients) and of skin malignancy (23 patients),⁵ we have observed 14 cases of nail disturbances. All these occurred in the treatment of 39 patients with periungual warts.

5-Fluorouracil was used as 5% in Neobase,^* 5% with 5% salicylic acid in Neobase, 20% in Neobase, and 20% with 5% salicylic acid in Neobase. All of these were used under adhesive. Controls in these experiments were 5% salicylic acid in Neobase and adhesive alone. Adhesive plaster with salicylic acid was not used as a control. Salicylic acid was used to . . . [Full Text PDF of this Article]

Author Affiliations
CINCINNATI

From The Department of Dermatology, University of Cincinnati Medical Center.

Footnotes
5-Fluorouracil furnished by Dr. Edward Miller, Department of Medical Investigation, Hoffmann-La Roche, Inc., Nutley, NJ.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?